FMP

FMP

Enter

CNTB - Connect Biopharma Ho...

Financial Summary of Connect Biopharma Holdings Limited(CNTB), Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the disco

photo-url-https://financialmodelingprep.com/image-stock/CNTB.png

Connect Biopharma Holdings Limited

CNTB

NASDAQ

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.

1.49 USD

-0.0084 (-0.563%)

About

ceo

Dr. Zheng Wei Ph.D.

sector

Healthcare

industry

Biotechnology

website

https://www.connectbiopharm.com

exchange

NASDAQ

Description

Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmu...

CIK

0001835268

ISIN

US2075231017

CUSIP

207523101

Address

East R&D Building

Phone

86 512 5357 7866

Country

CN

Employee

81

IPO Date

Mar 19, 2021

Summary

CIK

0001835268

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

207523101

ISIN

US2075231017

Country

CN

Price

1.49

Beta

-0.6

Volume Avg.

166.53k

Market Cap

82.19M

Shares

-

52-Week

0.535-2.84

DCF

1.38

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-1.38

P/B

-

Website

https://www.connectbiopharm.com

Historical Prices

We are unable to load the chart at this time.

fmp-logo

Financial Statement

We are unable to load the chart at this time.

fmp-logo

Earnings

We are unable to load the chart at this time.

fmp-logo

Upgrades and Downgrades

We are unable to load this data!

fmp-logo

People Also Watch

page loading card

Latest CNTB News

It looks like there's no news available.

fmp-logo
FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep